One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
- 13 July 2011
- journal article
- Published by S. Karger AG in Ophthalmologica
- Vol. 226 (3), 119-126
- https://doi.org/10.1159/000329466
Abstract
To evaluate the safety and efficacy of intravitreal ranibizumab with or without photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV) in Korean patients. A retrospective chart review of 22 patients (24 eyes) with PCV was conducted. Nine eyes were treated with intravitreal ranibizumab combined with a single session of PDT (group 1), and 15 eyes were treated only with ranibizumab (group 2). Such clinical evaluations as best-corrected Snellen visual acuity, central retinal thickness (CRT) by optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were done at baseline, 1, 3, 6, 9 and 12 months after the first injections. Ranibizumab was reinjected on an as-needed basis guided by OCT, FA and ICGA, or at the doctor's discretion. The mean follow-up duration was 22.5 months (range 12-37). The mean best-corrected visual acuity (logMAR) improved, and the mean CRT decreased throughout 12 months in both groups; no statistically significant difference between the groups was found (p = 0.327, p = 0.073, respectively). The number of ranibizumab injections was not significantly different either (p = 0.555). Intravitreal ranibizumab with or without PDT for PCV in Korean patients resulted in visual and anatomical improvement over the 1-year follow-up period.Keywords
This publication has 30 references indexed in Scilit:
- PHOTODYNAMIC THERAPY, RANIBIZUMAB, AND RANIBIZUMAB WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary studyBritish Journal of Ophthalmology, 2010
- Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal VasculopathyOphthalmologica, 2008
- The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal VasculopathyKorean Journal of Ophthalmology, 2008
- Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranesBritish Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow upClinical & Experimental Ophthalmology, 2005
- Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2004
- Polypoidal choroidal vasculopathy: natural history11InternetAdvance publication at ajo.com April 15, 2002.American Journal of Ophthalmology, 2002